Zydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust twenty-two percent increase in operational revenue, reaching eight thousand seventeen crore rupees. The company experienced profitability challenges with an EBITDA reduction of seven point six percent compared to the previous year. Following the announcement, their stock price saw an uptick. Zydus is a prominent player in the global pharmaceutical landscape.

AstraZeneca Pharma India reports Q1 profit drop to ₹37.93 crore despite revenue growth to ₹682.79 crore amid higher expenses.

Jubilant Pharmova shares fell after Q1 profit plunged 45% YoY to Rs 56 crore, despite revenue rising 17% to Rs 2,229 crore. The profit decline was attributed to weaker operating…